Nebulized Versus Intravenous Tranexamic Acid on Surgical Field Quality in Patients Undergoing Endoscopic Sinus Surgeries

Launched by CAIRO UNIVERSITY · Jan 11, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to give a medication called tranexamic acid during endoscopic sinus surgeries. Tranexamic acid helps reduce bleeding, which is important because even a small amount of blood can make it hard for doctors to see what they are doing during the surgery. The trial will compare giving this medication through a nebulizer (which turns the medicine into mist) versus giving it through an IV (intravenous). Researchers want to see which method results in better visibility and less bleeding during the procedure.

To participate in this trial, you should be between 18 and 60 years old and classified as a low-risk patient (ASA class I or II). You must be scheduled for endoscopic sinus surgery under general anesthesia. However, if you have any serious health issues, are on certain medications, or have had recent surgery-related complications, you may not be eligible. If you choose to participate, you will receive either the nebulized or IV form of tranexamic acid before your surgery, and the doctors will monitor how well it works in controlling bleeding and improving your surgical experience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 60 years.
• • American Society of Anesthesiologists (ASA) class I and II patients.
• • Endoscopic sinus surgeries under general anesthesia.
• Exclusion Criteria:
• • Patient's refusal.
• • American Society of Anesthesiologists (ASA) class III or IV patients.
• • Underlying uncontrolled hypertension.
• • Known history bleeding disorder.
• • Patients on anticoagulant therapy.
• • Allergy to any of the drugs utilized in this study.
• • History of nonsteroidal anti-inflammatory drugs within 48 hours of scheduled surgery.
• • Inadvertent intra-operative vascular injury.